OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors	539
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes	387
Translating IL-6 biology into effective treatments	352
Autoimmune and inflammatory diseases following COVID-19	280
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	275
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment	268
Synovial inflammation in osteoarthritis progression	232
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines	226
Global epidemiology of systemic lupus erythematosus	221
Emerging pharmaceutical therapies for osteoarthritis	202
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications	186
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	183
Systemic and organ-specific immune-related manifestations of COVID-19	181
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	172
IgG4-related disease: an update on pathophysiology and implications for clinical care	161
The gut–joint axis in rheumatoid arthritis	155
New insights into the role of antinuclear antibodies in systemic lupus erythematosus	139
COVID-19 revisiting inflammatory pathways of arthritis	137
Toll-like receptor signalling in B cells during systemic lupus erythematosus	137
Kawasaki disease: pathophysiology and insights from mouse models	135
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	126
Immune-mediated necrotizing myopathy: clinical features and pathogenesis	126
Early-stage symptomatic osteoarthritis of the knee — time for action	125
A new immunometabolic perspective of intervertebral disc degeneration	122
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	122

Cell-based strategies for IVD repair: clinical progress and translational obstacles	118
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	118
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	116
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis	114
Combating physical inactivity during the COVID-19 pandemic	112
Rheumatic disease and COVID-19: epidemiology and outcomes	111
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	109
Global epidemiology of vasculitis	108
Digital health technologies: opportunities and challenges in rheumatology	103
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	103
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	102
The non-coding RNA interactome in joint health and disease	100
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	97
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	93
Interplay between genetics and epigenetics in osteoarthritis	88
Oral surveillance and JAK inhibitor safety: the theory of relativity	87
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	83
PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets	77
Fibroblast growth factor signalling in osteoarthritis and cartilage repair	76
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response	75
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease	73
TNF in the era of immune checkpoint inhibitors: friend or foe?	72
Immune cartography of macrophage activation syndrome in the COVID-19 era	72
Axial spondyloarthritis: concept, construct, classification and implications for therapy	71
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic	71
The evolution of nerve growth factor inhibition in clinical medicine	69
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy	69
Sex steroids and autoimmune rheumatic diseases: state of the art	64
The endothelium–bone axis in development, homeostasis and bone and joint disease	64
Current and future therapies for primary Sjögren syndrome	63
Location, location, location: how the tissue microenvironment affects inflammation in RA	62
Interleukin-2 and regulatory T cells in rheumatic diseases	58